2757 studies found for:    (prostate cancer) [CONDITION]
Show Display Options
Rank Status Study
1 Active, not recruiting CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Conditions: Prostate Cancer;   Prostatic Cancer;   Prostatic Neoplasms;   Prostate Neoplasms;   Cancer of the Prostate
Intervention: Radiation: CyberKnife Stereotactic Radiosurgery
2 Active, not recruiting CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
Conditions: Prostate Cancer;   Prostatic Cancer;   Prostate Neoplasms;   Prostatic Neoplasms;   Cancer of the Prostate
Intervention: Radiation: CyberKnife Stereotactic Radiosurgery
3 Recruiting Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Conditions: Metastatic Prostate Cancer;   Cancer of the Prostate;   Prostate Cancer
Interventions: Drug: Anti-OX40;   Radiation: Radiation;   Drug: Cyclophosphamide
4 Active, not recruiting Sipuleucel-T Manufacturing Demonstration Study
Conditions: Cancer of Prostate;   Cancer of the Prostate;   Neoplasms, Prostate;   Neoplasms, Prostatic;   Prostate Cancer;   Prostate Neoplasms;   Prostatic Cancer
Intervention: Biological: sipuleucel-T
5 Completed A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
Conditions: Prostate Cancer;   Prostatic Neoplasms;   Cancer of the Prostate
Intervention: Drug: IPI-504
6 Not yet recruiting Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
Conditions: Prostate Cancer;   Metastatic Prostate Cancer;   Androgen-independent Prostate Cancer;   Recurrent Prostate Cancer
Intervention: Drug: onapristone
7 Active, not recruiting A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors
Conditions: Prostate Cancer;   Cancer of the Prostate;   Prostate Neoplasm
Intervention: Radiation: CyberKnife Radiosurgery
8 Active, not recruiting Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: abiraterone;   Drug: prednisone
9 Active, not recruiting Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: prednisone
10 Active, not recruiting Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: mitoxantrone;   Drug: prednisone
11 Terminated Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Conditions: Breast Cancer;   Lung Cancer;   Pulmonary Cancer;   Non-Small-Cell Lung Carcinoma;   Prostate Cancer;   Prostatic Cancer;   Gastric Cancer;   Stomach Cancer
Intervention: Drug: MGCD0103 & Docetaxel
12 Active, not recruiting A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Conditions: Prostate Neoplasms;   Prostate Cancer
Interventions: Drug: Cohort 4;   Drug: Cohort 3;   Drug: Cohort 2;   Drug: Cohort 1
13 Recruiting A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Conditions: Prostatic Neoplasms;   Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: JNJ-56021927
14 Recruiting Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer
Conditions: Prostate Cancer Recurrent;   Stage II Prostate Carcinoma;   Stage III Prostate Carcinoma
Intervention: Device: PET/MR
15 Recruiting Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Conditions: Breast Cancer;   Ovarian Epithelial Cancer Recurrent;   Sarcoma;   Non-small Cell Lung Cancer;   Carcinoma, Transitional Cell;   Prostate Cancer;   Prostatic Neoplasms
Intervention: Drug: Mifepristone and Eribulin in combination
16 Completed
Has Results
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
Conditions: Prostatic Neoplasms;   Prostate Cancer
Interventions: Drug: Abiraterone acetate;   Drug: Prednisone
17 Recruiting A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostrate Cancer and Men With Metastatic Prostate Cancer
Conditions: Prostate Cancer;   Metastatic Prostate Cancer;   Castration-resistant Prostate Cancer
Intervention:
18 Recruiting Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
Conditions: Prostatic Neoplasms;   Low Grade Prostate Cancer
Interventions: Other: Dietary intervention first;   Drug: Drug (Dutasteride) intervention first
19 Active, not recruiting Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage I Prostate Cancer;   Stage II Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Intervention: Radiation: intensity modulated external beam radiation therapy
20 Active, not recruiting MR Image Guided Therapy in Prostate Cancer
Conditions: Prostate Cancer;   Prostatic Neoplasms
Intervention: Device: Visualase Thermal Therapy System

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years